Market Overview

Amicus Extending Rally On Upgrades

Related FOLD
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Morning Market Gainers
Netflix's Cult Surprise - Cramer's Mad Money (1/21/15) (Seeking Alpha)

Amicus Therapeutics (NASDAQ: FOLD) shares are up 12 percent Tuesday following a nine percent jump Monday.

This move comes after JP Morgan, Janney and Leerink Partners upgraded Amicus to buy Monday and Tuesday and significantly boosted their price targets. The median price target is $5.50, or 45.1 percent of additional upside (65 percent before the stocks started moving higher).

Leerink thinks that the Phase 3 study has a high chance for success: 75 percent in Europe and 50 percent in the United States. This compares to a 20 percent success rate previously.

Related: Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

Leerink also expects top line results from study 012 at the end of July or beginning of August.

Shares of Amicus Were last trading up 12.5 percent in Tuesday’s pre-market session to $3.76. Shares have risen more than 42 percent in value year-to-date.

Latest Ratings for FOLD

Nov 2014JP MorganMaintainsOverweight
Jul 2014Janney CapitalUpgradesNeutralBuy
Jul 2014Leerink PartnersUpgradesMarket PerformOutperform

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Janney JP Morgan LeerinkUpgrades Movers & Shakers Price Target Analyst Ratings General


Related Articles (FOLD)

Around the Web, We're Loving...

Get Benzinga's Newsletters